Southeast Asia-focused venture capital firm SeaX Ventures has announced a $10 million investment in the seed funding round of U.S.-based biotech startup RyboDyn.
This funding aims to propel RyboDyn's innovative AI-driven platform, which targets the undiscovered "dark proteome" to identify novel cancer therapeutic targets from patient tumor samples.
Unlocking Hidden Cancer Targets with AI and Proteomics
RyboDyn integrates non-canonical RNA analysis, proteomics, and artificial intelligence to detect and validate cryptic proteins invisible to traditional sequencing methods.
The investment builds on SeaX Ventures' prior role as co-lead investor in RyboDyn's $4 million pre-seed round in early 2025, when the company emerged from stealth.
Founded in San Diego and a graduate of SOSV's IndieBio accelerator, RyboDyn has already forged key partnerships with Moffitt Cancer Center and Eli Lilly's Gateway Labs to validate its oncology discoveries.
SeaX Ventures, with offices in Bangkok and Silicon Valley, specializes in deep-tech investments across biotech, AI, and energy, leveraging Southeast Asian corporate networks for portfolio growth.
This latest round will advance RyboDyn's early-stage programs, including antibody-drug conjugates, toward clinical development stages.
By compiling a proprietary dataset like CypherAtlas™, RyboDyn enables repeatable discoveries across multiple cancer types, potentially revolutionizing immunotherapy options.
The collaboration highlights growing Southeast Asian VC interest in global U.S. biotech, bridging regional capital with cutting-edge cancer research for broader impact.
Future Implications for Oncology Innovation
Experts anticipate this funding could accelerate first-in-class treatments targeting the dark proteome, addressing unmet needs in precision oncology.
As cancer remains a leading global health challenge, initiatives like RyboDyn's underscore AI's transformative role in drug discovery and personalized medicine.
With this momentum, SeaX Ventures positions itself as a key player in fostering exponential technologies that expand from the U.S. into Southeast Asia and beyond.
Andrew Lee
